Unicycive Therapeutics Statistics Share Statistics Unicycive Therapeutics has 12.77M
shares outstanding. The number of shares has increased by 5.88%
in one year.
Shares Outstanding 12.77M Shares Change (YoY) 5.88% Shares Change (QoQ) 5.86% Owned by Institutions (%) 5.13% Shares Floating 11M Failed to Deliver (FTD) Shares 324 FTD / Avg. Volume 0.04%
Short Selling Information The latest short interest is 1.42M, so 11.13% of the outstanding
shares have been sold short.
Short Interest 1.42M Short % of Shares Out 11.13% Short % of Float 11.75% Short Ratio (days to cover) 1.72
Valuation Ratios The PE ratio is -14.48 and the forward
PE ratio is 0.26.
Unicycive Therapeutics's PEG ratio is
0.15.
PE Ratio -14.48 Forward PE 0.26 PS Ratio 0 Forward PS 0.1 PB Ratio 71.57 P/FCF Ratio -18.57 PEG Ratio 0.15
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Unicycive Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.28,
with a Debt / Equity ratio of 0.1.
Current Ratio 1.28 Quick Ratio 1.28 Debt / Equity 0.1 Debt / EBITDA -0.02 Debt / FCF -0.03 Interest Coverage -452.35
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.67M Employee Count 22 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -1.09M Effective Tax Rate 2.89%
Stock Price Statistics The stock price has increased by 16.57% in the
last 52 weeks. The beta is 1.87, so Unicycive Therapeutics's
price volatility has been higher than the market average.
Beta 1.87 52-Week Price Change 16.57% 50-Day Moving Average 5.53 200-Day Moving Average 5.89 Relative Strength Index (RSI) 36.6 Average Volume (20 Days) 724,305
Income Statement
Revenue n/a Gross Profit n/a Operating Income -32.12M Net Income -36.73M EBITDA -36.23M EBIT -37.9M Earnings Per Share (EPS) -0.06
Full Income Statement Balance Sheet The company has 26.14M in cash and 773K in
debt, giving a net cash position of 25.37M.
Cash & Cash Equivalents 26.14M Total Debt 773K Net Cash 25.37M Retained Earnings -101.27M Total Assets 27.95M Working Capital 10.67M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -28.57M
and capital expenditures -72K, giving a free cash flow of -28.65M.
Operating Cash Flow -28.57M Capital Expenditures -72K Free Cash Flow -28.65M FCF Per Share -0.43
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields UNCY does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for UNCY is $60,
which is 1396.3% higher than the current price. The consensus rating is "Buy".
Price Target $60 Price Target Difference 1396.3% Analyst Consensus Buy Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 20, 2025. It was a
backward
split with a ratio of 1:10.
Last Split Date Jun 20, 2025 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -7.53 Piotroski F-Score 2
